Compare UVSP & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | VTYX |
|---|---|---|
| Founded | 1876 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.5M | 990.9M |
| IPO Year | 1989 | 2021 |
| Metric | UVSP | VTYX |
|---|---|---|
| Price | $33.43 | $13.99 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 7 |
| Target Price | ★ $33.00 | $13.50 |
| AVG Volume (30 Days) | 144.6K | ★ 5.9M |
| Earning Date | 01-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 19.65 | N/A |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $309,144,000.00 | N/A |
| Revenue This Year | $13.32 | N/A |
| Revenue Next Year | $3.64 | N/A |
| P/E Ratio | $11.24 | ★ N/A |
| Revenue Growth | ★ 7.22 | N/A |
| 52 Week Low | $22.83 | $0.78 |
| 52 Week High | $35.65 | $25.00 |
| Indicator | UVSP | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 75.80 |
| Support Level | $32.96 | $13.94 |
| Resistance Level | $35.29 | $14.07 |
| Average True Range (ATR) | 0.84 | 0.05 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 40.61 | 77.42 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.